1 Department of Obstetrics & Gynaecology, Herlev University Hospital, DK-2730 Herlev and 2 Fertility Clinic, Rigshospitalet, DK-2100 Copenhagen Ø, Denmark
3 To whom correspondence should be addressed. Email: lidegaard{at}dadlnet.dk
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key words: cerebral palsy/imprinting/infertility/IVF
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Five recent reports have suggested an increased risk of imprinting diseases after IVF (Cox et al., 2002; DeBaun et al., 2003
; Gicquel et al., 2003
; Maher et al., 2003
; Moll et al., 2003
), and experimental studies have demonstrated that the culture media used in IVF may influence the imprinting process in animals (Khosla et al., 2001
; Young et al., 2001
).
Although the specific known imprinting diseases are all rare, they have serious consequences for the children.
In Denmark, the National IVF Registry was established in 1994 (Andersen et al., 1999). All clinics and hospitals, public as well as private, are by law obliged to report all treatment cycles to this register, including the personal identification number of the involved patient. Personal identification numbers of all children born after IVF with or without simultaneous ICSI can be identified by record-linkage of the IVF Registry with the National Birth Registry.
Since 1977, all discharge diagnoses from hospitals have been recorded in the National Register of Patients, and all psychiatric discharge diagnoses from clinics and hospitals in the National Register of Psychiatric Diseases (NRPD). These discharge diagnoses are recorded together with personal identification numbers of the patients. Since January 1, 1994, the WHO International Classification of Diseases, 10th revision, has been used in Denmark.
The aims of this study were to (i) assess the incidence rate of imprinting diseases in children born after and without IVF, and (ii) establish a cohort of Danish IVF and non-IVF singletons for regular follow-up.
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Women treated with IVF were identified in the IVF Registry. Subsequently, all established pregnancies were traced in the Birth Registry, which includes information on gestational age, and the personal identification numbers of mothers and children born. To approve a pregnancy as being a result of IVF treatment, the gestational age in the IVF Registry should match, within 2 weeks, the gestational age in the Birth Registry. For the year 2001, only children born after IVF initiated in the 2000 were included, because the registration in the IVF Registry for 2001 was not completed. Therefore, 300 IVF children born during the last 3 months of 2001 were misclassified as non-IVF children; however, they constitute less than one in 1000 of the control children.
All specific diagnosis codes for known imprinting diseases were included, as well as codes for diseases that might have been used in children with clinical symptoms but who had not been diagnosed with the specific imprinting disorder. The specific codes included in the study are indicated in Table I. In- as well as out-patients were included, and primary diagnoses as well as secondary diagnosis codes were included. Not all imprinting diseases had a specific diagnosis code during the study period, the most important omission being for Angelman syndrome.
|
Each child was allowed to be counted only once with a diagnosis in each of the five main diagnosis groups (Table I). In case of more diagnoses within the same main diagnosis group, a priority according to the specificity for imprinting diseases was established (Table I). This arbitrary 19 ranking (1 had highest specificity) of diseases was performed prior to data retrieval.
Incidence rates of main diagnosis groups and of each specific diagnosis included were calculated for IVF and non-IVF children. Secondly, incidence rate ratios (IRR) between IVF and non-IVF children were established. Ninety-five per cent confidence intervals (95% CI) were calculated for these IRRs.
Permission to link data in the IVF registry, the National Register of Patients and the Central Register of Psychiatric Diseases was achieved by Datatilsynet (Board of Registers=Danish Data Protection Agency), j. No. 2003-41-3048.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In the non-IVF cohort, the number of detected cancers was 72, specified mental diseases 3766, neurological diseases 3654, congenital malformations/syndromes 287 and developmental disturbances 6727, in a total of 14 506 clinical outcomes (Table I). The corresponding number of diseases in the IVF cohort was 0, 47, 72, 4 and 96, in a total of 219 clinical outcomes (Table I).
The incidence of specific diagnoses in the two cohorts and the corresponding IRRs between the IVF and the non-IVF cohort are indicated in Table I. The absolute number of cases with each diagnosis in the IVF cohort and calculated IRRs are indicated in Figure 1.
|
Based on 20/819 cases in the IVF/non-IVF cohorts, we found a significantly increased risk of cerebral palsy after IVF; 3.3 versus 1.9 per 1000, and an IRR of 1.8 (95% CI 1.22.8). Sleeping disturbances were also detected more frequently in the IVF cohort: IRR 2.0 (1.23.3).
The incidence rates of the included main diagnosis groups of childhood cancers (DC), mental diseases (DF), congenital syndromes (DQ) and developmental disturbances (DR) were equal in the two cohorts.
Five diseases had statistically non-significant increased IRRs, ranging from 2 to 3 (Table I and Figure 1), each with few cases in the IVF cohort. These diseases were hemiparesis (IRR 2.0), diseases of the autonomous nervous system (IRR 2.4), syndromes with dwarf growth (IRR 2.4), motor retardation (IRR 2.8) and anorexia (IRR 2.6), and they constitute an observational group that will be paid special attention in our future follow-up of these cohorts.
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The diagnosis of imprinting diseases, however, is difficult. Many of the syndromes have a broad clinical spectrum, different molecular pathogenesis, and the infant has to reach a certain age before these diseases become clinically detectable. It was therefore supposed that many children with these diseases were not recorded with the specific diagnosis code for these syndromes.
With 54 imprinting diseases among 442 349 singleton children born without prior IVF, or 12 per 100 000 children, the expected number of these syndromes in the IVF cohort was below one, anticipating the same frequency in the two cohorts. This finding first of all indicates that a significant number of imprinting diseases are misclassified during the first years of children's life. It is not very likely, however, that the misclassification of these diagnoses occurred differentially in the IVF and non-IVF cohort. The fact that we did not find any children with these diagnoses in the IVF group within a follow-up period of 4.1 years is an encouraging indication that these diseases do not occur more frequent among IVF children than among children born without IVF. Larger multicentre or transnational studies need to confirm this finding. Although some authors have questioned whether these cancers are or could be imprinting diseases, a single study reported an association between retinoblastoma and IVF (Moll et al., 2003). Whether an imprinting disease or not, our data were not able to exclude an increased risk of this specific cancer, due to the rarity of this disease.
An increased risk of cerebral palsy in IVF singletons was also demonstrated in a Swedish follow-up of 3183 IVF singletons by Strömberg et al. (2002). They found an IRR of 2.8 (95% CI 1.35.8), and no differential risk after stratification for maternal age. We have not found other assessments of the frequency of cerebral palsy in IVF singletons versus controls.
Although some imprinting syndromes might be misclassified with the diagnosis of cerebral palsy, especially during the first years of life, such a misclassification hardly explains the 80% demonstrated increased risk of this disease. IVF mothers are on average 34 years older than the mothers of non-IVF children. Lidegaard (2004) found, in a Danish Register study, a slightly increasing frequency of cerebral palsy with increasing age. After stratification for parity, this increase was only detectable in primiparous women >35 years old. As IVF mothers constitute 2025% of all primiparous women >35 years old, an increased risk of cerebral palsy after IVF might fully explain this age-trend in primiparous women.
Premature birth (before week 37) in IVF singletons is slightly more frequent (7.3%) than in non-IVF singletons (5.3%) (Westergaard et al., 1999). This difference, however, could only explain about one-fifth of the increased risk of cerebral palsy in our IVF singletons, and the rate ratio of cerebral palsy among IVF singletons was of same magnitude in mature (
37 weeks) and in premature (<37 weeks) children.
Pharoah and Adi (2000) demonstrated a 40-fold increased risk of cerebral palsy in a twin surviving death (mainly in the third trimester) of the other twin in utero, so called vanishing twins. The risk of cerebral palsy in vanishing twins due to death in first or second trimester has not been assessed.
In a review, Landy and Keith (1998) concluded that
30% of all twin pregnancies ultimately result in singletons. In our IVF clinic, over the last 3 years, we had 723 clinical pregnancies at 7 weeks of gestation, 519 (72%) singletons, 43 (6%) vanishing twins and 161 (22%) twins. If Landy and Keith's estimate is correct, according to our data, (43 + 161 x 0.30)/(519 + 43 + 48), or
15%, of all singleton children born after IVF are vanishing twins. If the risk of cerebral palsy among vanishing twins established in the first or second trimester is not 40-fold but, for example, four times increased, that would increase the incidence rate of cerebral palsy by
45% in IVF singletons.
If vanishing twins are the only explanation of the increased risk of cerebral palsy in IVF singletons, we would not expect an increased risk of cerebral palsy in IVF twins as compared with age-matched non-IVF twins. In the study by Strömberg et al. (2002) and in a recent Danish study (Pinborg et al., 2004
), no increased risk of cerebral palsy was demonstrated in IVF twins as compared with non-IVF twins, supporting that vanishing twins could be a contributing explanation of the increased risk of cerebral palsy found in singletons after IVF treatment.
The doubled frequency of sleeping disturbances could be influenced by the older parents in the IVF children. Older parents probably have a lower threshold for referring their child to investigation in case of sleeping disturbances. We have not found similar results in other published follow-up data.
Regular follow-up of this National Danish IVF cohort will be carried out in the Danish registers during the coming years.
In conclusion, we found fewer specific imprinting diagnoses in both IVF and non-IVF children than expected, and with this limitation, no indication was found of an increased risk of imprinting diseases in children born after IVF as compared with children born without prior IVF. We observed equal frequencies of childhood cancers, mental diseases, congenital syndromes and developmental disturbances in the two cohorts, but an 80% increased risk of cerebral palsy in singletons born after IVF.
![]() |
Acknowledgements |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cox GF, Bürger J, Lop V, Mau UA, Sperling K, Wu B-L and Horsthemke B (2002) Intracytoplasmic sperm injection may increase the risk of imprinting defects. Am J Hum Genet 71, 162164.[CrossRef][ISI][Medline]
DeBaun MR, Niemitz L and Feinberg AP (2003) Association of in vitro fertilization with Beckwith-Wiedemann syndrome and epigenetic alterations of LIT1 and H19. Am J Hum Genet 72, 156160.[CrossRef][ISI][Medline]
Gicquel C, Gaston V, Mandelbaum J, Siffroi J-P, Flahault A and Bouc YL (2003) In vitro fertilisation may increase the risk of Beckwith-Wiedemann syndrome related to the abnormal imprinting of the KCNQ1OT gene. Am J Hum Genet 72, 13381341.[CrossRef][ISI][Medline]
Khosla S, Dean W, Brown D, Reik W and Feil R (2001) Culture of preimplantation mouse embryos affects fetal development and the expression of imprinted genes. Biol Reprod 64, 918926.
Landy HJ and Keith LG (1998) The vanishing twin: a review. Hum Reprod Update 4, 177183.
Lidegaard AP (2004) Birth weight and the risk of complications in newborn and mother. Master thesis. Copenhagen University, Institute of Public Health, Copenhagen, Denmark (PDF version available on-line at www.dachre.dk).
Maher ER, Brueton LA, Bowdin SC, Luharia A, Cooper W, Cole TR, Macdonald F, Sampson JR, Barratt CL, Reik W et al. (2003) Beckwith-Wiedemann syndrome and assisted reproduction technology (ART). J Med Genet 40, 6264.
Moll AC, Imhof SM, Cruysberg JRM, Meeteren AYNS-V, Boers M and Leeuwen FEV (2003) Incidence of retinoblastoma in children born after in-vitro fertilisation. Lancet 361, 309310.[CrossRef][ISI][Medline]
Pharoah POD and Adi Y (2000) Consequences of in-utero death in a twin pregnancy. Lancet 355, 15971602.[CrossRef][ISI][Medline]
Pinborg A, Loft A, Schmidt L, Gresien G, Rasmussen S and Andersen AN (2004) Neurological sequelae in twins born after assisted conception: controlled national cohort study. BMJ 329, 311314.
Strömberg B, Dahlquist G, Ericson A, Finnström O, Köster M and Stjernqvist K (2002) Neurological sequelae in children born after in-vitro fertilisation: a population-based study. Lancet 359, 461465.[CrossRef][ISI][Medline]
Westergaard HB, Johansen AMT, Erb K and Andersen AN (1999) Danish National In-Vitro Fertilization Registry 1994 and 1995: a controlled study of births, malformations and cytogenetic findings. Hum Reprod 14, 18961902.
Young LE, Fernandes K, McEvoy TG, Butterwith SC, Gutierrez CG, Carolan C, Broadbent PJ, Robinson JJ, Wilmut I and Sinclair KD (2001) Epigenetic change in IGF2R is associated with fetal overgrowth after sheep embryo culture. Nat Genet 27, 153154.[CrossRef][ISI][Medline]
Submitted on July 12, 2004; resubmitted on September 15, 2004; accepted on December 3, 2004.